×
About 49,418 results

ALLMedicine™ Cystic Fibrosis Center

Research & Reviews  23,783 results

Sleep assessment in cystic fibrosis patients using a minimal-impact biomotion system.
https://doi.org/10.1016/j.sleep.2021.04.019
Sleep Medicine; Linker CM, Straßburg S et. al.

May 14th, 2021 - In our study we aimed to analyze sleep variability and activity in patients with cystic fibrosis (CF) during their hospital stay. Forty-three CF patients were recruited and have been divided into two subgroups: exacerbated (n = 18) and non-exacerb...

The measurement properties of tests and tools used in cystic fibrosis studies: a system...
https://doi.org/10.1183/16000617.0354-2020
European Respiratory Review : an Official Journal of the ... McLeod C, Wood J et. al.

May 13th, 2021 - There is no consensus on how best to measure responses to interventions among children and adults with cystic fibrosis (CF). We have systematically reviewed and summarised the characteristics and measurement properties of tests and tools that have...

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of No...
https://doi.org/10.1007/s40262-021-01010-4 10.1007/s40262-018-0678-x 10.1007/s11046-017-0189-6 10.2165/00003088-199835040-00004 10.2165/00003495-198835050-00004 10.1042/BCJ20190324 10.1513/AnnalsATS.201709-727OC 10.1097/MCP.0b013e328365ab33 10.3389/fimmu.2020.00303 10.1183/13993003.00046-2017 10.1093/cid/ciy531 10.1136/thoraxjnl-2015-207360 10.1136/bmjresp-2017-000242 10.1164/rccm.200604-571ST 10.1136/thoraxjnl-2015-207983 10.1016/j.chest.2016.05.003 10.1093/cid/ciw724 10.1136/thoraxjnl-2017-210927 10.2174/1381612820666140901215544 10.1016/j.tube.2017.11.004 10.1128/AAC.00695-08 10.1164/rccm.201204-0682OC 10.1093/cid/ciaa1125 10.1016/j.cmi.2019.01.019 10.1016/j.dld.2014.06.011 10.1016/j.pedhc.2015.07.010 10.1186/1743-7075-6-50 10.1128/AAC.01522-06 10.1136/archdischild-2018-314972 10.1007/s00228-010-0851-0 10.1128/AAC.49.12.5013-5017.2005 10.1128/AAC.05710-11 10.1128/AAC.40.1.6 10.3390/ijms21228586 10.3748/wjg.v19.i46.8552 10.1046/j.1365-2125.2002.01625.x 10.1007/s12551-008-0002-3 10.1007/s00467-010-1737-1 10.1002/ppul.22669 10.1023/A:1008634911114 10.1128/AAC.27.4.583 10.1128/AAC.00936-09 10.1016/j.chest.2018.06.002 10.1093/clinids/7.Supplement_3.S435 10.2165/00003495-199651010-00008 10.1128/AAC.01411-17 10.1111/1469-0691.12405 10.1128/JCM.00298-16 10.3389/fmicb.2018.02179 10.3389/fmicb.2018.02273 10.1128/AAC.02623-18 10.1093/jac/23.1.99 10.1128/AAC.23.2.323 10.1128/AAC.00585-16 10.1093/jac/dku431 10.1128/AAC.02763-14 10.1136/ejhpharm-2019-001875 10.1164/rccm.200905-0704OC 10.1186/s12879-017-2665-5 10.3390/ijms18051062 10.1164/rccm.201807-1318OC 10.1164/rccm.201604-0700OC 10.2147/DDDT.S146111 10.3389/fmicb.2018.00915 10.1007/s40265-019-01095-z 10.1089/jamp.2008.0693 10.1128/AAC.00872-08 10.1111/resp.12676 10.1093/cid/ciy613 10.1128/AAC.00961-16 10.1002/ppul.24468 10.1002/ppul.24194 10.1128/AAC.02282-15 10.1128/AAC.00990-16 10.1086/420742 10.1128/AAC.01050-15 10.1164/rccm.201906-1206OC 10.1093/jac/26.4.533 10.1002/ppul.21620 10.1097/01.ftd.0000195617.69721.a5 10.2165/00044011-200121050-00005 10.1186/s40780-015-0029-0 10.1128/AAC.02854-15 10.1164/rccm.201111-2005OC 10.2165/00003088-199937050-00003 10.1016/j.jcf.2013.08.008 10.1016/j.ijid.2016.12.027 10.3389/fmicb.2018.02642 10.1128/AAC.02360-17 10.1128/JCM.00274-17 10.1128/AAC.01797-10 10.1128/AAC.48.1.281-284.2004 10.1002/ppul.20966 10.5588/ijtld.16.0113 10.1016/j.diagmicrobio.2017.09.013 10.1097/FTD.0000000000000710 10.1016/j.ijantimicag.2013.02.020 10.1016/j.ebiom.2015.09.051 10.1128/AAC.02522-18 10.1128/AAC.01135-17 10.1093/jac/dku062 10.1093/jac/dkl224 10.1517/17425255.2011.623126 10.1128/AAC.03112-15 10.1016/j.rmed.2019.10.006 10.1128/AAC.00283-18 10.1128/AAC.02234-18 10.1111/j.1365-2125.1991.tb03920.x 10.1128/AAC.01208-18 10.1093/jac/dkz143 10.2165/00003088-197803020-00002 10.1016/j.ijantimicag.2014.04.019 10.1007/s40262-019-00764-2 10.1186/1476-0711-5-3 10.1002/jcph.968 10.1002/ppul.23505 10.1007/s00228-012-1429-9 10.1007/s00228-010-0914-2 10.1016/j.ijantimicag.2013.03.010 10.1128/AAC.00155-17 10.1128/AAC.00274-11 10.1128/AAC.05623-11 10.1186/s12890-019-0982-8 10.1128/AAC.01355-09 10.1128/AAC.00491-18 10.1128/AAC.02615-15 10.1093/jac/43.5.615 10.1128/AAC.01505-12 10.1089/mdr.2017.0286 10.1128/AAC.00072-18 10.1016/S2213-2600(16)30121-7 10.1056/NEJMoa1409547 10.1124/dmd.117.078691 10.1046/j.1365-2125.2000.00261.x 10.1056/NEJMoa1908639 10.1124/dmd.117.077834 10.1007/s10620-015-3834-2 10.1016/j.jcf.2007.05.005 10.1155/2004/747841 10.1093/jac/dkh072 10.1128/AAC.00877-18 10.1093/jac/48.2.325 10.1007/BF01644141 10.1159/000238979 10.1093/jac/dky152 10.1128/AAC.47.7.2118-2124.2003 10.1093/jac/dkp262 10.1128/AAC.50.4.1170-1177.2006 10.1080/0036554021000026963 10.1097/00006454-199711000-00013 10.1128/AAC.01761-09 10.1128/AAC.01036-07 10.1592/phco.21.16.233S.33992 10.1016/j.ijantimicag.2009.09.023 10.1128/AAC.00260-15 10.1002/cpt1974156610 10.1093/clinids/5.Supplement_3.S428 10.1128/AAC.43.3.568 10.1128/AAC.00770-16 10.1097/FTD.0b013e3181cc6d6f 10.1128/AAC.01468-05 10.1159/000048494 10.1093/jac/dkw426 10.1016/j.tube.2004.04.001 10.1128/AAC.01032-15 10.5588/ijtld.16.0791 10.2165/11317100-000000000-00000 10.1007/BF02282885
Clinical Pharmacokinetics; Burke A, Smith D et. al.

May 13th, 2021 - Non-tuberculous mycobacteria (NTM) are an emerging group of pulmonary infectious pathogens of increasing importance to the management of patients with cystic fibrosis (CF). NTM include slow-growing mycobacteria such as Mycobacterium avium complex ...

Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary ...
https://doi.org/10.1002/ppul.25441
Pediatric Pulmonology; Ochs MA, Dillman NO et. al.

May 13th, 2021 - Aminoglycosides are commonly used for the treatment of Pseudomonas aeruginosa (PsA) in the setting of acute pulmonary exacerbations (PEx) in pediatric patients with cystic fibrosis (CF). There are controversies and practice differences between ins...

SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control...
https://doi.org/10.1371/journal.pone.0251527
PloS One; Colombo C, Alicandro G et. al.

May 13th, 2021 - To describe the symptoms and clinical course of SARS-CoV-2 infection in patients with cystic fibrosis (CF). We carried out a prospective multicentre cohort study based on 32 CF centres and 6597 patients. Centres were contacted to collect baseline ...

see more →

Guidelines  85 results

Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evide...
https://doi.org/10.1016/j.jand.2020.03.015
Journal of the Academy of Nutrition and Dietetics; McDonald CM, Alvarez JA et. al.

Jun 22nd, 2020 - The Academy of Nutrition and Dietetics Evidence Analysis Center conducted a systematic review of the literature to develop an evidence-based practice guideline for primary nutrition issues in cystic fibrosis (CF). This guideline is designed to com...

Direct-to-consumer genetic testing
https://www.ama-assn.org/delivering-care/precision-medicine/direct-consumer-genetic-testing

Apr 2nd, 2019 - Types of DTC genetic tests A broad range of genetic test types are offered DTC, including: Carrier testing for diseases such as cystic fibrosis and hemochromatosis Pharmacogenomic testing Testing for predisposition to complex diseases such as her...

Practice Advisory: Cell-free DNA to Screen for Single-Gene Disorders
https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Cell-free-DNA-to-Screen-for-Single-Gene-Disorders

Feb 20th, 2019 - The continued innovation in cell-free technology combined with the desire for a maternal blood test to predict the risk for fetal genetic disorders during a pregnancy has broadened the application of cell-free DNA screening beyond aneuploidy to si...

Home Oxygen Therapy for Children. An Official American Thoracic Society Clinical Practice Guideline
https://www.atsjournals.org/doi/full/10.1164/rccm.201812-2276ST
Hayes,D.,et al

Jan 31st, 2019 - Although home oxygen therapy is commonly required in the care of children, there is a striking lack of empirical evidence regarding implementation, monitoring, and discontinuation of supplemental oxygen therapy. The panel formulated and provided t...

Nutritional Considerations in Pediatric Pancreatitis: A Position Paper from the NASPGHA...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020697
Journal of Pediatric Gastroenterology and Nutrition; Abu-El-Haija M, Uc A et. al.

Jun 21st, 2018 - Wide variations exist in how physicians manage the nutritional aspects of children affected by acute pancreatitis (AP), acute recurrent pancreatitis (ARP), and chronic (CP) pancreatitis. Better consensus for optimal management is needed. This cons...

see more →

Drugs  95 results see all →

Clinicaltrials.gov  24,589 results

Sleep assessment in cystic fibrosis patients using a minimal-impact biomotion system.
https://doi.org/10.1016/j.sleep.2021.04.019
Sleep Medicine; Linker CM, Straßburg S et. al.

May 14th, 2021 - In our study we aimed to analyze sleep variability and activity in patients with cystic fibrosis (CF) during their hospital stay. Forty-three CF patients were recruited and have been divided into two subgroups: exacerbated (n = 18) and non-exacerb...

The measurement properties of tests and tools used in cystic fibrosis studies: a system...
https://doi.org/10.1183/16000617.0354-2020
European Respiratory Review : an Official Journal of the ... McLeod C, Wood J et. al.

May 13th, 2021 - There is no consensus on how best to measure responses to interventions among children and adults with cystic fibrosis (CF). We have systematically reviewed and summarised the characteristics and measurement properties of tests and tools that have...

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of No...
https://doi.org/10.1007/s40262-021-01010-4 10.1007/s40262-018-0678-x 10.1007/s11046-017-0189-6 10.2165/00003088-199835040-00004 10.2165/00003495-198835050-00004 10.1042/BCJ20190324 10.1513/AnnalsATS.201709-727OC 10.1097/MCP.0b013e328365ab33 10.3389/fimmu.2020.00303 10.1183/13993003.00046-2017 10.1093/cid/ciy531 10.1136/thoraxjnl-2015-207360 10.1136/bmjresp-2017-000242 10.1164/rccm.200604-571ST 10.1136/thoraxjnl-2015-207983 10.1016/j.chest.2016.05.003 10.1093/cid/ciw724 10.1136/thoraxjnl-2017-210927 10.2174/1381612820666140901215544 10.1016/j.tube.2017.11.004 10.1128/AAC.00695-08 10.1164/rccm.201204-0682OC 10.1093/cid/ciaa1125 10.1016/j.cmi.2019.01.019 10.1016/j.dld.2014.06.011 10.1016/j.pedhc.2015.07.010 10.1186/1743-7075-6-50 10.1128/AAC.01522-06 10.1136/archdischild-2018-314972 10.1007/s00228-010-0851-0 10.1128/AAC.49.12.5013-5017.2005 10.1128/AAC.05710-11 10.1128/AAC.40.1.6 10.3390/ijms21228586 10.3748/wjg.v19.i46.8552 10.1046/j.1365-2125.2002.01625.x 10.1007/s12551-008-0002-3 10.1007/s00467-010-1737-1 10.1002/ppul.22669 10.1023/A:1008634911114 10.1128/AAC.27.4.583 10.1128/AAC.00936-09 10.1016/j.chest.2018.06.002 10.1093/clinids/7.Supplement_3.S435 10.2165/00003495-199651010-00008 10.1128/AAC.01411-17 10.1111/1469-0691.12405 10.1128/JCM.00298-16 10.3389/fmicb.2018.02179 10.3389/fmicb.2018.02273 10.1128/AAC.02623-18 10.1093/jac/23.1.99 10.1128/AAC.23.2.323 10.1128/AAC.00585-16 10.1093/jac/dku431 10.1128/AAC.02763-14 10.1136/ejhpharm-2019-001875 10.1164/rccm.200905-0704OC 10.1186/s12879-017-2665-5 10.3390/ijms18051062 10.1164/rccm.201807-1318OC 10.1164/rccm.201604-0700OC 10.2147/DDDT.S146111 10.3389/fmicb.2018.00915 10.1007/s40265-019-01095-z 10.1089/jamp.2008.0693 10.1128/AAC.00872-08 10.1111/resp.12676 10.1093/cid/ciy613 10.1128/AAC.00961-16 10.1002/ppul.24468 10.1002/ppul.24194 10.1128/AAC.02282-15 10.1128/AAC.00990-16 10.1086/420742 10.1128/AAC.01050-15 10.1164/rccm.201906-1206OC 10.1093/jac/26.4.533 10.1002/ppul.21620 10.1097/01.ftd.0000195617.69721.a5 10.2165/00044011-200121050-00005 10.1186/s40780-015-0029-0 10.1128/AAC.02854-15 10.1164/rccm.201111-2005OC 10.2165/00003088-199937050-00003 10.1016/j.jcf.2013.08.008 10.1016/j.ijid.2016.12.027 10.3389/fmicb.2018.02642 10.1128/AAC.02360-17 10.1128/JCM.00274-17 10.1128/AAC.01797-10 10.1128/AAC.48.1.281-284.2004 10.1002/ppul.20966 10.5588/ijtld.16.0113 10.1016/j.diagmicrobio.2017.09.013 10.1097/FTD.0000000000000710 10.1016/j.ijantimicag.2013.02.020 10.1016/j.ebiom.2015.09.051 10.1128/AAC.02522-18 10.1128/AAC.01135-17 10.1093/jac/dku062 10.1093/jac/dkl224 10.1517/17425255.2011.623126 10.1128/AAC.03112-15 10.1016/j.rmed.2019.10.006 10.1128/AAC.00283-18 10.1128/AAC.02234-18 10.1111/j.1365-2125.1991.tb03920.x 10.1128/AAC.01208-18 10.1093/jac/dkz143 10.2165/00003088-197803020-00002 10.1016/j.ijantimicag.2014.04.019 10.1007/s40262-019-00764-2 10.1186/1476-0711-5-3 10.1002/jcph.968 10.1002/ppul.23505 10.1007/s00228-012-1429-9 10.1007/s00228-010-0914-2 10.1016/j.ijantimicag.2013.03.010 10.1128/AAC.00155-17 10.1128/AAC.00274-11 10.1128/AAC.05623-11 10.1186/s12890-019-0982-8 10.1128/AAC.01355-09 10.1128/AAC.00491-18 10.1128/AAC.02615-15 10.1093/jac/43.5.615 10.1128/AAC.01505-12 10.1089/mdr.2017.0286 10.1128/AAC.00072-18 10.1016/S2213-2600(16)30121-7 10.1056/NEJMoa1409547 10.1124/dmd.117.078691 10.1046/j.1365-2125.2000.00261.x 10.1056/NEJMoa1908639 10.1124/dmd.117.077834 10.1007/s10620-015-3834-2 10.1016/j.jcf.2007.05.005 10.1155/2004/747841 10.1093/jac/dkh072 10.1128/AAC.00877-18 10.1093/jac/48.2.325 10.1007/BF01644141 10.1159/000238979 10.1093/jac/dky152 10.1128/AAC.47.7.2118-2124.2003 10.1093/jac/dkp262 10.1128/AAC.50.4.1170-1177.2006 10.1080/0036554021000026963 10.1097/00006454-199711000-00013 10.1128/AAC.01761-09 10.1128/AAC.01036-07 10.1592/phco.21.16.233S.33992 10.1016/j.ijantimicag.2009.09.023 10.1128/AAC.00260-15 10.1002/cpt1974156610 10.1093/clinids/5.Supplement_3.S428 10.1128/AAC.43.3.568 10.1128/AAC.00770-16 10.1097/FTD.0b013e3181cc6d6f 10.1128/AAC.01468-05 10.1159/000048494 10.1093/jac/dkw426 10.1016/j.tube.2004.04.001 10.1128/AAC.01032-15 10.5588/ijtld.16.0791 10.2165/11317100-000000000-00000 10.1007/BF02282885
Clinical Pharmacokinetics; Burke A, Smith D et. al.

May 13th, 2021 - Non-tuberculous mycobacteria (NTM) are an emerging group of pulmonary infectious pathogens of increasing importance to the management of patients with cystic fibrosis (CF). NTM include slow-growing mycobacteria such as Mycobacterium avium complex ...

Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary ...
https://doi.org/10.1002/ppul.25441
Pediatric Pulmonology; Ochs MA, Dillman NO et. al.

May 13th, 2021 - Aminoglycosides are commonly used for the treatment of Pseudomonas aeruginosa (PsA) in the setting of acute pulmonary exacerbations (PEx) in pediatric patients with cystic fibrosis (CF). There are controversies and practice differences between ins...

SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control...
https://doi.org/10.1371/journal.pone.0251527
PloS One; Colombo C, Alicandro G et. al.

May 13th, 2021 - To describe the symptoms and clinical course of SARS-CoV-2 infection in patients with cystic fibrosis (CF). We carried out a prospective multicentre cohort study based on 32 CF centres and 6597 patients. Centres were contacted to collect baseline ...

see more →

News  821 results

Immediate Treatment of M. Abscessus Urged for Cystic Fibrosis
https://www.medscape.com/viewarticle/950846

May 10th, 2021 - NEW YORK (Reuters Health) - An analysis of whole genome data from cystic fibrosis patients reveals how multi-drug resistant pathogens evolve and suggests that Mycobacterium abscessus infection be treated promptly, contrary to current medical pract...

Can a 'Sweat Sticker' Improve Diagnosis of Cystic Fibrosis?
https://www.medscape.com/viewarticle/948591

Mar 31st, 2021 - A soft, flexible device that sticks on skin to capture sweat and measure sweat chloride may help doctors diagnose cystic fibrosis in infants, according to new data published online March 31 in Science Translational Medicine. But not everyone is co...

Money, Talent Flowing Into mRNA Sector After COVID-19 Success
https://www.medscape.com/viewarticle/947434

Mar 15th, 2021 - (Reuters) - The success of COVID-19 vaccines based on messenger RNA (mRNA) is smoothing the way for using the novel technology not only in other vaccines, but possibly as treatments for cystic fibrosis, cancer and other hard-to-treat diseases. Sci...

Fast Five Quiz: Spinal Muscular Atrophy Clinical Presentation
https://reference.medscape.com/viewarticle/944574

Jan 31st, 2021 - Spinal muscular atrophy (SMA) consists of a group of autosomal-recessive disorders characterized by progressive weakness of the lower motor neurons. Estimates suggest 1 in 6000 to 1 in 10,000 individuals are affected, making SMA the second most co...

Telehealth Finds Acceptance Among Patients With Cf, Clinicians
https://www.medscape.com/viewarticle/941411

Nov 22nd, 2020 - Telehealth is widely accepted among individuals with cystic fibrosis (CF) and the physicians who treat them, according to three new studies. The surveys examined attitudes during the COVID-19 pandemic, which complicates interpretation of the surve...

see more →

Patient Education  45 results see all →